Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA608126
Max Phase: Preclinical
Molecular Formula: C64H99N13O11
Molecular Weight: 1226.58
Molecule Type: Small molecule
Associated Items:
ID: ALA608126
Max Phase: Preclinical
Molecular Formula: C64H99N13O11
Molecular Weight: 1226.58
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@@H]1NC(=O)[C@H](CCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(NC(=O)C(C)C)cc2)NC1=O
Standard InChI: InChI=1S/C64H99N13O11/c1-36(2)32-46-57(81)72-48(34-41-18-12-11-13-19-41)63(87)76-30-16-22-50(76)59(83)74-52(38(5)6)61(85)69-45(21-15-29-66)56(80)71-47(33-37(3)4)58(82)73-49(35-42-24-26-43(27-25-42)67-54(78)40(9)10)64(88)77-31-17-23-51(77)60(84)75-53(39(7)8)62(86)68-44(20-14-28-65)55(79)70-46/h11-13,18-19,24-27,36-40,44-53H,14-17,20-23,28-35,65-66H2,1-10H3,(H,67,78)(H,68,86)(H,69,85)(H,70,79)(H,71,80)(H,72,81)(H,73,82)(H,74,83)(H,75,84)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
Standard InChI Key: XKPJOSUKKNRHPF-XBJFMILWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1226.58 | Molecular Weight (Monoisotopic): 1225.7587 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. van der Knaap M, Engels E, Busscher HJ, Otero JM, Llamas-Saiz AL, van Raaij MJ, Mars-Groenendijk RH, Noort D, van der Marel GA, Overkleeft HS, Overhand M.. (2009) Synthesis and biological evaluation of asymmetric gramicidin S analogues containing modified D-phenylalanine residues., 17 (17): [PMID:19674904] [10.1016/j.bmc.2009.07.042] |
Source(1):